Bristol Myers Squibb Press Releases https://bristolmyers2016ir.q4web.com/generated by Q4Tue, 21 Jul 2026 09:59:25 -0400Copyright Q4 Inc. All rights reserved.Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA8c9397b5-f92e-45f1-8ee7-578b6f4a00c0https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspxMon, 20 Jul 2026 06:59:00 -0400U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma5940acab-e238-4eab-8cb8-5bbaa1be65abhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxMon, 13 Jul 2026 06:59:00 -0400Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026fdf1bdda-8191-4192-b48e-07e4cc8b5659https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-to-Report-Results-for-Second-Quarter-2026-on-July-30-2026/default.aspxThu, 18 Jun 2026 06:59:00 -0400Bristol Myers Squibb Announces Dividend8fed0070-b0f9-43e0-9881-4f56f0d1885ehttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Dividend-d189f3983/default.aspxWed, 17 Jun 2026 16:16:00 -0400Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease2c9c508b-5d33-4e0c-a153-a9752a534267https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Mariska-Hargitay-Partners-with-Bristol-Myers-Squibb-for-Investigating-Myeloma-Awareness-Campaign-to-Honor-Her-Father-20-Years-After-Losing-Him-to-the-Disease/default.aspxMon, 08 Jun 2026 06:59:00 -0400Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinomac2cea402-b479-4df7-b813-f0ccab0f378bhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspxTue, 02 Jun 2026 08:00:00 -0400U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)e85cda85-38ca-42b7-9c9f-45de22fda2cehttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/U-S--Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Supplemental-New-Drug-Application-for-Camzyos-mavacamten-to-Treat-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspxMon, 01 Jun 2026 06:59:00 -0400Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma3a04bfd1-2c98-4d78-a2b7-b5c27993617bhttps://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-Opdivo-nivolumab-in-Combination-with-AVD-Receives-Expanded-EU-Label-with-Approval-in-Frontline-Advanced-Classical-Hodgkin-Lymphoma/default.aspxMon, 01 Jun 2026 06:55:00 -0400Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trialeabf73db-8ba7-410c-9abc-1499d3870c08https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Global-Data-for-BioNTech-and-Bristol-Myers-Squibbs-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Trial/default.aspxSat, 30 May 2026 14:15:00 -0400Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma62d15b9c-8f5c-4576-a7ec-0f3f203fa463https://bristolmyers2016ir.q4web.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Announces-CELMoD-Mezigdomide-Reduces-Risk-of-Disease-Progression-or-Death-by-More-than-50-vs--Standard-of-Care-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspxFri, 29 May 2026 08:00:00 -0400